The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity.
The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) has been shown to synergize doxorubicin (Dox) anticancer activity while attenuating its cardiotoxicity. In this study we further explored the selectivity of AN-7's action in several cancer and normal cells treated with anticancer agents. The cells studied were murine mammary 4T1, human breast T47D and glioblastoma U251 cancer cell lines, neonatal rat cardiomyocytes, cardiofibroblasts and astrocytes, and immortalized cardiomyocyte H9C2 cells. Cell death, ROS production and changes in protein expression were measured and in vivo effects were evaluated in Balb-c mice. AN-7 synergized Dox and anti-HER2 cytotoxicity against mammary carcinoma cells with combination indices of 0.74 and 0.79, respectively, while it protected cardiomyocytes against their toxicity. Additionally AN-7 protected astrocytes from Dox-cytoxicity. Cell-type specific changes in the expression of proteins controlling survival, angiogenesis and inflammation by AN-7 or AN-7+Dox were observed. In mice, the protective effect of AN-7 against Dox cardiotoxicity was associated with a reduction in inflammatory factors. In summary, AN-7 augmented the anticancer activity of Dox and anti-HER2 and attenuated their toxicity against normal cells. AN-7 modulation of c-Myc, thrombospondin-1, lo-FGF-2 and other proteins were cell type specific. The effects of AN-7, Dox and their combination were preserved in vivo indicating the potential benefit of combining AN-7 and Dox for clinical use.
Tarasenko
Nataly
N
Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel-Aviv University, Beilinson Campus, Petach-Tikva 49100, Israel.
Kessler-Icekson
Gania
G
Boer
Pnina
P
Inbal
Aida
A
Schlesinger
Hadassa
H
Phillips
Don R
DR
Cutts
Suzanne M
SM
Nudelman
Abraham
A
Rephaeli
Ada
A
D042501:Angiogenic Proteins / Q000378:metabolism; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000633:toxicity; D001253:Astrocytes / Q000187:drug effects* / Q000473:pathology; D001932:Brain Neoplasms / Q000201:enzymology / Q000473:pathology*; D001943:Breast Neoplasms / Q000201:enzymology / Q000276:immunology / Q000473:pathology*; D002087:Butyrates / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D019610:Cytoprotection; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D004357:Drug Synergism; D005260:Female; D005347:Fibroblasts / Q000187:drug effects* / Q000473:pathology; D005909:Glioblastoma / Q000201:enzymology / Q000473:pathology*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D020128:Inhibitory Concentration 50; D051379:Mice; D008807:Mice, Inbred BALB C; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000473:pathology; D009943:Organophosphorus Compounds / Q000494:pharmacology; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D013997:Time Factors
D042501:Angiogenic Proteins; D000906:Antibodies; D002087:Butyrates; D004317:Doxorubicin; D056572:Histone Deacetylase Inhibitors; D018836:Inflammation Mediators; D009943:Organophosphorus Compounds; D017382:Reactive Oxygen Species; D018719:Erb-b2 Receptor Tyrosine Kinases; C502471:diethoxyphosphoryloxymethyl butanoate; C508053:ERBB2 protein, human